Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.

[1]  C. Yancy,et al.  Adherence to Heart Failure Quality-of-Care Indicators in US Hospitals. Analysis of the ADHERE Registry , 2005 .

[2]  A. Mebazaa,et al.  Randomized clinical trials with levosimendan. , 2005, The American journal of cardiology.

[3]  C. Yancy,et al.  Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. , 2005, Archives of internal medicine.

[4]  G. W. Dec,et al.  Acute decompensated heart failure: the shrinking role of inotropic therapy. , 2005, Journal of the American College of Cardiology.

[5]  K. Adams,et al.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.

[6]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[7]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[8]  N. Freemantle,et al.  Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING‐UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta‐analysis of cardiac resynchronisation therapy , 2004, European journal of heart failure.

[9]  C. O'connor,et al.  Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. , 2004, American heart journal.

[10]  H. Grassos,et al.  273 Comparison of the effect of levosimendan, or dobutamin or placebo in chronic low output decompensated heart failure. CAlcium sensitizer or Inotrope or NOne in low output heart failure (CASINO) study , 2004 .

[11]  R. Shannon,et al.  Catecholamines restore myocardial contractility in dilated cardiomyopathy at the expense of increased coronary blood flow and myocardial oxygen consumption (MvO2 cost of catecholamines in heart failure) , 2004, European journal of heart failure.

[12]  A. Cohen-Solal,et al.  Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure , 2004, Critical Care.

[13]  W. Bleifeld,et al.  Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and lack of tolerance , 1992, Cardiovascular Drugs and Therapy.

[14]  P. F. F. G. R. Heyndrickx M.D..  Hibernating myocardium , 2004, Basic Research in Cardiology.

[15]  G. Fonarow,et al.  The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[16]  L. Stevenson,et al.  Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. , 2003, Circulation.

[17]  J. Prestle,et al.  Ca(2+)-handling proteins and heart failure: novel molecular targets? , 2003, Current medicinal chemistry.

[18]  J. Petruk-Kowalczyk.  [Beta-blockers in chronic heart failure]. , 2003, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[19]  K. Swedberg,et al.  &bgr;-Blockers in Chronic Heart Failure , 2003, Circulation.

[20]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[21]  J. Aranda,et al.  Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. , 2003, American heart journal.

[22]  M. Metra,et al.  Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. , 2002, Journal of the American College of Cardiology.

[23]  N. Freemantle,et al.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure—a meta‐regression analysis , 2002, European journal of heart failure.

[24]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[25]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[26]  R. Shannon,et al.  Catecholamine stimulation is associated with impaired myocardial O(2) utilization in heart failure. , 2002, Cardiovascular research.

[27]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[28]  J. Papp,et al.  STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL , 2002 .

[29]  M. Bristow,et al.  Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. , 2001, International journal of cardiology.

[30]  A. Jain,et al.  Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. , 2001, American heart journal.

[31]  A. Stephanou,et al.  Apoptosis of Endothelial Cells Precedes Myocyte Cell Apoptosis in Ischemia/Reperfusion Injury , 2001, Circulation.

[32]  R. Feneck,et al.  Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. , 2001, Journal of cardiothoracic and vascular anesthesia.

[33]  M. Verani,et al.  Altered Adrenergic Receptor Density in Myocardial Hibernation in Humans: A Possible Mechanism of Depressed Myocardial Function , 2000, Circulation.

[34]  S. Ogawa,et al.  Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. , 2000, The American journal of cardiology.

[35]  N. Dhalla,et al.  Sarcoplasmic reticulum Ca(2+)/Calmodulin-dependent protein kinase is altered in heart failure. , 2000, Circulation research.

[36]  M. Bristow,et al.  Inotropes in the beta‐blocker era , 2000, Clinical cardiology.

[37]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[38]  M. S. Walton,et al.  Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. , 2000, Circulation.

[39]  M. Bristow.  beta-adrenergic receptor blockade in chronic heart failure. , 2000, Circulation.

[40]  J. Canty,et al.  Profound apoptosis-mediated regional myocyte loss and compensatory hypertrophy in pigs with hibernating myocardium. , 1999, Circulation.

[41]  A. Kitabatake,et al.  Myocardial high-energy phosphate metabolism in patients with stable chronic dilated cardiomyopathy under a dobutamine-induced prolonged mild workload. , 1999, American heart journal.

[42]  R. Bonow,et al.  Prognostic implications of myocardial contractile reserve in patients with coronary artery disease and left ventricular dysfunction. , 1999, Journal of the American College of Cardiology.

[43]  A. Maggioni,et al.  Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. , 1999, American heart journal.

[44]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[45]  J. Cleland,et al.  The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS) , 1999, European journal of heart failure.

[46]  D. DeMets,et al.  A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure , 1998 .

[47]  A. Katz,et al.  Is the failing heart energy depleted? , 1998, Cardiology clinics.

[48]  Lawrence Buja,et al.  Modes of myocardial cell injury and cell death in ischemic heart disease. , 1998, Circulation.

[49]  S. Vatner,et al.  Hibernating myocardium. , 1998, The New England journal of medicine.

[50]  M. Lishner,et al.  Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: A randomized, double‐blind, placebo‐controlled study , 1998, Clinical pharmacology and therapeutics.

[51]  W. Abraham,et al.  Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. , 1998, Journal of the American College of Cardiology.

[52]  V. Gil.  [Hibernating myocardium. An incomplete adaptation to ischemia]. , 1998, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[53]  J. Feinglass,et al.  Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. , 1997, American heart journal.

[54]  F. Harrell,et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[55]  A. Skene,et al.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure , 1997, The Lancet.

[56]  T. Takano,et al.  Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. , 1996, Critical care medicine.

[57]  J. Lubsen,et al.  Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. , 1996, Heart.

[58]  A. DeMaria,et al.  Comparative efficacy of short‐term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction , 1996, Clinical cardiology.

[59]  M. Piepoli,et al.  Effects of pulsed β-stimulant therapy on β-adrenoceptors and chronotropic responsiveness in chronic heart failure , 1995, The Lancet.

[60]  T. Takano,et al.  MULTICENTER DOUBLE‐BLIND STUDY OF INTRAVENOUS MILRINONE FOR PATIENTS WITH ACUTE HEART FAILURE IN JAPAN , 1995 .

[61]  M. Piepoli,et al.  Effects of pulsed beta-stimulant therapy on beta-adrenoceptors and chronotropic responsiveness in chronic heart failure. , 1995, Lancet.

[62]  M. Schwaiger,et al.  Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[63]  G. Heusch,et al.  Development of Short‐term Myocardial Hibernation Its Limitation by the Severity of Ischemia and Inotropic Stimulation , 1993, Circulation.

[64]  W. Remme.  Inodilator therapy for heart failure. Early, late, or not at all? , 1993, Circulation.

[65]  G. Heusch,et al.  Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation. , 1992, Circulation research.

[66]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[67]  J. Anderson,et al.  Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. , 1991, American heart journal.

[68]  C. Oakley.  Genesis of arrhythmias in the failing heart and therapeutic implications. , 1991, American Journal of Cardiology.

[69]  S. Kunitada,et al.  Functional and metabolic effects of bucladesine (dibutyryl cyclic AMP) in the working rat heart preparation: comparison with dopamine. , 1989, Archives internationales de pharmacodynamie et de therapie.

[70]  R. Kloner,et al.  Altered myocardial states. The stunned and hibernating myocardium. , 1989, The American journal of medicine.

[71]  A. Katz.  Cellular mechanisms in congestive heart failure. , 1988, The American journal of cardiology.

[72]  D. Salem,et al.  Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1987, The American journal of cardiology.

[73]  D. Faxon,et al.  Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. , 1987, The American journal of cardiology.

[74]  D. Baim,et al.  Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. , 1987, Journal of the American College of Cardiology.

[75]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[76]  E. Braunwald,et al.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. , 1986, The New England journal of medicine.

[77]  E. Braunwald,et al.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. , 1986, The New England journal of medicine.

[78]  D. Baim,et al.  Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. , 1986, Circulation.

[79]  H. White,et al.  Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure. , 1985, The American journal of cardiology.

[80]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[81]  M. Packer,et al.  Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. , 1984, Circulation.

[82]  C. Liang,et al.  Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. , 1984, Circulation.

[83]  C. Leier,et al.  Drug-induced conditioning in congestive heart failure. , 1982, Circulation.

[84]  A. Katz.  A new inotropic drug: its promise and a caution. , 1978, The New England journal of medicine.